Equities Analysts Issue Forecasts for IGC Pharma Q1 Earnings

IGC Pharma, Inc. (NYSEAMERICAN:IGC) – Ascendiant Capital Markets issued their Q1 2028 earnings per share estimates for shares of IGC Pharma in a report released on Tuesday, April 7th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings per share of ($0.02) for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $5.25 price target on the stock. The consensus estimate for IGC Pharma’s current full-year earnings is ($0.11) per share. Ascendiant Capital Markets also issued estimates for IGC Pharma’s Q2 2028 earnings at ($0.02) EPS, Q3 2028 earnings at ($0.02) EPS, Q4 2028 earnings at ($0.02) EPS and FY2028 earnings at ($0.08) EPS.

IGC Pharma Price Performance

NYSEAMERICAN IGC opened at $0.31 on Tuesday. IGC Pharma has a one year low of $0.24 and a one year high of $0.50. The stock has a 50-day moving average of $0.27 and a 200 day moving average of $0.32. The company has a market capitalization of $30.63 million, a price-to-earnings ratio of -4.43 and a beta of 0.30. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.89 and a current ratio of 1.32.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IGC. Virtu Financial LLC boosted its position in IGC Pharma by 91.0% in the third quarter. Virtu Financial LLC now owns 89,546 shares of the company’s stock worth $37,000 after purchasing an additional 42,654 shares during the last quarter. Citadel Advisors LLC boosted its position in IGC Pharma by 131.7% in the third quarter. Citadel Advisors LLC now owns 627,840 shares of the company’s stock worth $262,000 after purchasing an additional 356,874 shares during the last quarter. Finally, State Street Corp boosted its position in IGC Pharma by 25.3% in the fourth quarter. State Street Corp now owns 200,799 shares of the company’s stock worth $57,000 after purchasing an additional 40,592 shares during the last quarter. 3.87% of the stock is owned by hedge funds and other institutional investors.

About IGC Pharma

IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc and changed its name to IGC Pharma, Inc in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.